The UK and US have concluded a landmark commercial pact that will preserve zero levies on British pharmaceutical products being sold in the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to increase spending on drugs through the public health system. This move ensures that duties on these crucial products will be held at zero for a duration of three years.
This deal comes after recent statements to dramatically increase import taxes on patented drug imports, with figures floated up to one hundred percent.
"This arrangement with the Britain reinforces the worldwide climate for cutting-edge drugs and introduces much-needed balance to American-British drug exports," a release said.
Commercial Significance
Medicines are one of the Britain's most significant exports to the America, which is by far the biggest buyer for large companies like GSK and AstraZeneca.
Statistics show that in the 12 months prior to September, the UK exported pharmaceutical products valued at £11.1bn to the US. This amount made up 17.4% of all goods exports in that timeframe.
"This guarantee protects work, boosts funding and sets the stage for the UK to become a global hub for biotech and pharma," a minister remarked.
Specific British Pledges
The pact includes several specific commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it considers new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to raise total health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the next decade.
- Payback Limit: The percentage manufacturers must pay back to the NHS to prevent overspending will be restricted at 15%. Last year, repayments were more than 20%.
Recent Tensions
This agreement follows a protracted dispute between the sector and the UK government over drug pricing and NHS adoption.
The disagreement were intensified by arguments that US consumers were paying several times more for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or abandoned, while major funding commitments have been pledged toward US facilities.
A senior figure stated that the NHS had to increase expenditure on treatments, noting that its spending on drugs had declined as a proportion of its overall budget over the previous ten-year period.
